Clinical Trials

Blue Faery: The Adrienne Wilson Liver Cancer Association

AA

A A

Clinical Trials

Print Friendly, PDF & Email

Clinical trials are studies conducted on volunteers using investigational treatments or methods. The decision to enroll in a trial should be based on concrete information and eligibility depends on many factors. For more information about HCC clinical trials in your area, visit www.clinicaltrials.gov.

  • Discuss the advantages, disadvantages and side effects of treatment options with your doctor.
  • Ask your doctor about the possibility of using experimental therapies and eligibility to participate in clinical trials. If you want to participate in clinical trial, ask what is the phase of the trial.
  • Consider seeking a second opinion if your health insurance allows you the option to do so.


Liver Cancer Clinical Trials (featured listings)

Blue Faery does not endorse, sponsor or recommend any specific clinical trial. An asterisk indicates a paid listing.

The HistoSonics System for Treatment of Primary and Metastatic Liver Tumors Using Histotripsy (#HOPE4LIVER US)

The objective of this trial is to evaluate the efficacy and safety of the HistoSonics System for the treatment of primary or metastatic tumors located in the liver.

Official Title: The HistoSonics System for Treatment of Primary and Metastatic Liver Tumors Using Histotripsy (#HOPE4LIVER US)
Condition: Hepatocellular Carcinoma
Intervention/Treatment: Histotripsy
Phase: NA–Medical Device Pivotal Trial
Study Type: This trial is a single-arm, non-randomized prospective trial.
Study Design: Clinical Trial
Primary Purpose: Treatment

For more information, contact Sr. Clinical Trials Manager Zoe Secord
Email: zoe.secord@histosonics.com
Website: https://histosonics.com

Business Phone: (763) 300-7313

HistoSonics Inc
16305 36th Ave
North Plymouth, MN 55446 United States
Map It

Listed on 8/30/21


A Global Study to Assess the Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment (EMERALD-2)*

This is a Phase III, randomized, double-blind, placebo-controlled, multi-center, global study to assess the efficacy and safety of durvalumab in combination with bevacizumab or durvalumab monotherapy or placebo as adjuvant therapy. This study will be conducted in patients with HCC who are at high risk of recurrence after curative hepatic resection or ablation.

Official Title: A Global Study to Assess the Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment (EMERALD-2)
Condition: Hepatocellular Carcinoma
Intervention/Treatment: Durvalumab / placebo and Bevacizumab / placebo
Phase: Phase III
Study Type: Interventional (Clinical Trial)
Study Design: Parallel assignment
Primary Purpose: Treatment

For more information, contact James Osborne, Global Clinical Operations Program Director
Email: information.center@astrazeneca.com
Website: https://astrazenecagrouptrials.pharmacm.com/

Business Phone: (877) 240-9479

AstraZeneca
200 Orchard Ridge Drive
Gaithersburg, MD 20878
United States
Map It

Listed on 8/14/21 


A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation (IMbrave050)*

This study will evaluate the efficacy and safety of adjuvant therapy with atezolizumab plus bevacizumab compared with active surveillance in participants with completely resected or ablated hepatocellular carcinoma (HCC) who are at high risk for disease recurrence.

Official Title: A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation (IMbrave050)
Condition: Hepatocellular Carcinoma
Intervention/Treatment: Parallel Assignment
Phase: Phase III
Study Type: Interventional (Clinical Trial)
Study Design: Randomized
Primary Purpose: Treatment

For more information, contact Karen Cravotto, Associate Director, Clinical Operations
Email: global.rochegenentechtrials@roche.com
Website: https://www.roche.com/about_roche/roche_worldwide.htm

Business Phone: (888) 662-6728

Hoffmann-La Roche
1 DNA Way
South San Francisco, CA 94080
United States
Map It

Listed on 8/10/21 


An Open-Label, Dose-Escalation, Multi-Center Phase I/II Clinical Trial of ECT204 T-Cell Therapy in Adults with Advanced Hepatocellular Carcinoma (HCC) (ARYA-3)*

The purpose of this study is to assess the safety and tolerability of ECT204 T cells in adult patients with glypican-3 (GPC3) positive hepatocellular carcinoma (HCC) and to determine the recommended Phase 2 dose (RP2D). ECT204 T cells are autologous T cells engineered to specifically recognize and kill GPC3 positive liver cancer cells.

Official Title: An Open-Label, Dose-Escalation, Multi-Center Phase I/II Clinical Trial of ECT204 T-Cell Therapy in Adults With Advanced Hepatocellular Carcinoma (HCC) (ARYA-3)
Condition: Advanced hepatocellular carcinoma
Intervention/Treatment: ECT204 T cells
Phase: Phase I/II
Study Type: Interventional (Clinical Trial)
Study Design: Sequential Assignment, Open Label
Primary Purpose: Treatment

For more information, contact Karen Cravotto, Associate Director, Clinical Operations
Email: karen.cravotto@eurekainc.com
Website: https://www.eurekaconnectme.com
Phone (510) 722-8719
Business Phone: (510) 654-7045

Eureka Therapeutics, Inc.
5858 Horton Street, Suite 170
Emeryville, CA 94608
United States
Map It

Listed on 7/22/21 


Clinical Trial for the IvyGene Liver Cancer Test (CLiMB)*

This is a clinical trial designed to evaluate the performance of the IvyGene Dx Liver Cancer Test alone, ultrasound alone, and the combination of both the IvyGene Dx Liver Cancer Test and ultrasound for the detection of HCC within a population that is at high risk for HCC due to liver cirrhosis.

The IvyGene Dx Liver Cancer Test is designed to measure proteins and DNA fragments in blood that are associated with liver cancer. This is a multi-site, prospective study, to compare the standard of care for liver cancer surveillance in individuals with cirrhosis (ultrasound) to the IvyGene Dx Liver Cancer Test, individually or in combination.

Eligible and consented patients will undergo an ultrasound, multiphasic MRI, and a blood draw at the first visit. Patients with indeterminate LI-RADS 3 scores (indeterminate for liver cancer) will undergo additional follow-up visits every 6 months (up to 3 follow-up visits) until the patient is determined to be positive or negative for liver cancer.
Patients will be compensated for their participation.

Official Title: Prospective Clinical Trial to Detect Liver Cancer Through Quantification of cfDNA Methylation in Blood Samples: A LAM Insight Trial Study
Condition: Patients at high risk for Hepatocellular Carcinoma due to liver cirrhosis
Intervention/Treatment: Diagnostic Test — IvyGene DX Liver Cancer Test
Phase: Phase III
Study Type: Observational, Multi-site Prospective
Study Design: Cohort Study
Primary Purpose: Early detection

For more information, contact Justin Li, CEO US Region
Email: justin@heliohealth.com
Website: https://www.heliohealth.com
Phone: (949) 463-3307

Helio Health
9950 Research Drive
Irvine, CA 92618
United States
Map It

Listed on 7/14/21 


Open-label, Dose Escalation Clinical Trial (ARYA-1) of ET140203 T Cell Therapy in Adult Patients with Advanced Hepatocellular Carcinoma (HCC)*

The purpose of this study is to assess the safety and tolerability of ET140203 T cells in adult patients with Alpha-fetoprotein (AFP)-positive/Human Leukocyte Antigen (HLA) A-2-positive advanced hepatocellular carcinoma (HCC) and to determine the recommended Phase 2 dose (RP2D). ET140203 T cells are autologous T cells engineered to specifically recognize and kill AFP/HLA-A2 positive liver cancer cells.

Condition: Advanced Hepatocellular Carcinoma
Intervention: ET140203 T cells
Phase: Phase I/II
Study Type: Interventional (Clinical Trial)
Study Design: Sequential Assignment, Open Label
Primary Purpose: Treatment

For more information, contact Karen Cravotto, Associate Director, Clinical Operations
Email: karen.cravotto@eurekainc.com
Website: https://www.eurekaconnectme.com
Phone (510) 722-8719
Business Phone: (510) 654-7045

Eureka Therapeutics, Inc.
5858 Horton Street, Suite 170
Emeryville, CA 94608
United States
Map It

Listed on 6/12/21 


A Phase II, Randomized, Controlled Trial of Nivolumab in Combination With BMS-986253 or Cabiralizumab in Advanced Hepatocellular Carcinoma (HCC) Patients*

Phase II clinical trial for advanced-stage hepatocellular carcinoma (HCC) patients to receive nivolumab or nivolumab plus BMS-986253 (anti-IL8) treatment. Candidates must have Child's Class A or better liver disease. Fresh pre-treatment and on-treatment biopsies required.

Condition: Hepatocellular carcinoma
Intervention: nivolumab or nivolumab plus BMS-986253 (anti-IL8)
Phase: Phase II
Study Type: clinical/interventional
Study Design: Randomized phase II
Primary Purpose: Treatment

For more information, contact Dr. Theodore Welling.
Email: Theodore.Welling@nyulangone.org
Website: https://nyulangone.org/locations/liver-tumor-program
Phone (212) 731-5617

Theodore Welling
Associate Prof. of Surgery
NYU Langone Health, Perlmutter Cancer Center
160 East 34th Street
New York, NY 10016
United States
Map It

Listed on 4/12/21 


Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar)

This early phase I trial studies the side effects of autologous dendritic cells and a vaccine called Prevnar in treating patients with liver cancer that cannot be remove by surgery after undergoing standard high-dose external beam radiotherapy. Autologous dendritic cells are immune cells generated from patients' own white blood cells that are grown in a special lab and trained to stimulate the immune system to destroy tumor cells. A pneumonia vaccine called Prevnar may also help stimulate the immune system. Giving autologous dendritic cells and Prevnar to patients with live cancer after radiotherapy may help doctors determine if it is possible to stimulate the body's own immune system to fight against the tumor, and to see if this immune stimulation can be done safely.

Condition: Hepatocellular carcinoma
Intervention: Combination of external beam radiation therapy, pneumonia (Prevnar) vaccine and autologous dendritic cells
Phase: Phase 1
Study Type: Interventional (Clinical Trial)
Study Design: Single arm, open label
Primary Purpose: Treatment

For more information, contact Dr. Lewis Roberts, Director, Hepatobiliary Neoplasia Clinic
Email: Roberts.Lewis@mayo.edu
Website: https://www.mayo.edu/research/faculty/roberts-lewis-r-m-b-ch-b-ph-d/bio-00084430
Phone (507) 266-3239

Mayo Clinic
200 First Street SW
Rochester, MN 55905
United States
Map It

Listed on 9/22/20


A Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (LEAP-012)*

The purpose of this study is to evaluate the efficacy and safety of lenvatinib and pembrolizumab in combination with TACE versus TACE plus oral and intravenous (IV) placebos in participants with incurable, non-metastatic hepatocellular carcinoma (HCC). The primary hypotheses are that pembrolizumab plus lenvatinib in combination with TACE is superior to placebo plus TACE with respect to progression-free survival (PFS) and overall survival (OS).

Condition: Hepatocellular carcinoma
Intervention: Drug: Lenvatinib Biological: Pembrolizumab Drug: Oral Placebo Drug: IV Placebo Procedure: TACE
Phase: Phase 3
Study Type: Interventional
Study Design: Allocation: Randomized Intervention, Model: Parallel Assignment, Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment

For more information, email: Trialsites@merck.com

Medical Director
Merck Sharp & Dohme Corp.
2000 Galloping Hill Road
Kenilworth, New Jersey 07033
United States
Map It
Business Phone (888) 577-8839

Listed on 8/28/20


A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma and Complete Radiological Response After Surgical Resection or Local Ablation (KEYNOTE-937)*

This study will evaluate the safety and efficacy of pembrolizumab (MK-3475) versus placebo as adjuvant therapy in participants with hepatocellular carcinoma (HCC) and complete radiological response after surgical resection or local ablation. The primary hypotheses of this study are that adjuvant pembrolizumab is superior to placebo with respect to: 1) recurrence-free survival (RFS) as assessed by blinded independent central review (BICR); and 2) overall survival (OS).

Condition: Hepatocellular carcinoma
Intervention: Biological: Pembrolizumab IV infusion of Pembrolizumab 200 mg. Other Names: KEYTRUDA® MK-3475 • Drug: Placebo IV infusion of 0.9% normal saline
Phase: Phase 3
Study Type: Interventional
Study Design: Allocation is Randomized, Intervention Model isParallel Assignment, Masking is Double (Participant, Investigator)
Primary Purpose: Treatment

For more information, email: Trialsites@merck.com

Business Phone (888) 577-8839

Medical Director
Merck Sharp & Dohme Corp.
2000 Galloping Hill Road
Kenilworth, New Jersey 07033
United States
Map It

Listed on 8/28/20


A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma (EMERALD-1)*

This is a randomized, double-blind, placebo-controlled, multicenter, global Phase III study to determine the efficacy and safety of transarterial chemoembolization (TACE) treatment in combination with durvalumab monotherapy or TACE given with durvalumab plus bevacizumab therapy compared to TACE therapy alone in patients with locoregional hepatocellular carcinoma not amenable to curative therapy.

Condition: Hepatocellular carcinoma
Intervention: Drug: Durvalumab Drug: Bevacizumab Other: Placebo Procedure: Transarterial Chemoembolization (TACE)
Phase: Phase III
Study Type: Interventional
Study Design: Parallel Assignment
Primary Purpose: Treatment

For more information, email: information.center@astrazeneca.com

AstraZeneca Clinical Study Information Center
Business Phone: 1-877-240-9479

Listed on 1/22/19


A Phase 2, Open-Label Study With Orally Administered CVM-1118 and Sorafenib in Subjects With Advanced Hepatocellular Carcinoma*

CVM-1118 is a new small molecule chemical entity being developed as a potential anti-cancer therapeutic by TaiRx, Inc. CVM-1118 is a potent anti-cancer agent in numerous human cancer cell lines. The safety of administrating CVM-1118 on human is evaluated from the phase 1 study. The objectives of the phase 2 study is to further investigate the efficacy of CVM-1118 with sorafenib for subjects with advanced hepatoma.

Condition: Hepatocellular carcinoma
Intervention: CVM-1118
Phase: Phase 2
Study Type: Interventional
Study Design: Single Group Assignment, Open Label
Primary Purpose: Treatment

For more information, email kdorr@sciquus.com

Kirsten Dorr, Senior Project Manager
Cell Phone: (858) 337-2927

SciQuus Oncology Inc.
4250 Executive Square, Suite 450
La Jolla, CA 92037
United States
Map It
Business Phone: (858) 642-0386

Listed on 1/22/19


*Indicates a paid listing